Incyte Corporation (BMV:INCY)

Market Cap	367.83B +28.7%
Revenue (ttm)	88.28B +18.1%
Net Income	21.80B +3,559.2%
EPS	108.27 +3,878.0%
Shares Out	n/a
PE Ratio	16.87
Forward PE	13.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,240
Average Volume	993
Open	1,875.60
Previous Close	1,774.25
Day's Range	1,873.00 - 1,875.60
52-Week Range	1,180.69 - 1,995.00
Beta	n/a
RSI	62.20
Earnings Date	Feb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD